Amer Hawatmeh, MD
Interventional Cardiology · Jonesboro, ARNPI 1942668082
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Medtronic at 35.7% of the total. Reporting peaked in 2019 at $8,033 and has fallen 78.3% since, to $1,747 in 2025.
Across 296 payments — averaging $65.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Edwards Lifesciences$4K
- Abbott$2K
- Boston Scientific$2K
- Penumbra, Inc.$1K
- Abiomed$1K
- plus $2K from 23 others
What the payments were for
- Grants$6,50033%
- Travel & lodging$3,02916%
- Food & beverage$9,98951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $6,965 |
| Edwards Lifesciences | 73 | $3,791 |
| Abbott | 41 | $2,363 |
| Boston Scientific | 70 | $1,862 |
| Penumbra, Inc. | 15 | $1,133 |
| Abiomed | 16 | $1,016 |
| Cardiovascular Systems Inc. | 23 | $803 |
| Shockwave Medical, Inc | 2 | $367 |
| AstraZeneca | 4 | $204 |
| Amgen | 6 | $157 |
| Avinger Inc. | 7 | $153 |
| Cvrx, Inc. | 2 | $109 |
| E.r. Squibb & Sons, L.L.C. | 2 | $94 |
| Cardinal Health 200 LLC | 3 | $71 |
| W. L. Gore & Associates, Inc. | 4 | $69 |
| Heartflow, Inc. | 1 | $57 |
| Terumo Medical Corporation | 2 | $34 |
| Livanova USA, Inc. | 1 | $33 |
| Biosense Webster, Inc. | 1 | $31 |
| Novartis | 2 | $30 |
| Portola Pharmaceuticals, LLC | 2 | $28 |
| Angiodynamics, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Pfizer | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$6,500
- MitraClip$1,081
- Indigo System$774
- Edwards SAPIEN 3 Transcatheter Heart Valve$629
- Impella$406
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$367
- AVVIGO Guidance System$149
- Peripheral Orbital Atherectomy System$141
- GENERAL - THERAPIES$141
- CoreValve Evolut$137
- Penumbra System$130
- Perclose ProGlide suture mediated closure system$103
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$102
- SAPIEN 3 Ultra RESILIA$102
- GENERAL - STENTS$101
How this compares
$19,518 in reported general payments places this provider in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $191,844 |
| Repatha SureclickEvolocumab | 42 | $60,965 |
| EntrestoSacubitril/Valsartan | 77 | $51,359 |
| JardianceEmpagliflozin | 60 | $47,903 |
| FarxigaDapagliflozin Propanediol | 40 | $35,467 |
| Praluent PenAlirocumab | 22 | $31,225 |
| VascepaIcosapent Ethyl | 42 | $19,146 |
| BrilintaTicagrelor | 29 | $13,260 |
| XareltoRivaroxaban | 18 | $11,375 |
| Atorvastatin Calcium | 644 | $4,472 |
| Ezetimibe | 177 | $3,108 |
| ClopidogrelClopidogrel Bisulfate | 325 | $2,318 |
| Metoprolol Succinate | 195 | $1,672 |
| Midodrine Hcl | 19 | $1,186 |
| Carvedilol | 246 | $1,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $191,844278 claims |
| NovartisEntresto | $30 | $51,35977 claims |
| AstraZenecaFarxiga, Brilinta | $204 | $48,72769 claims |
| Boehringer IngelheimJardiance | $15 | $47,90360 claims |
| Johnson & JohnsonXarelto | $25 | $11,37518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Jonesboro
- Lena AwarJonesboro$43K
- Ahmed AhmedJonesboro$19K
- Roger HillJonesboro$10K
- John McKeeJonesboro$7K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Zubair AhmedFayetteville$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.